Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866590 · ClinicalTrials.gov registry record
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)
A clinical trial, sponsored by CENTOGENE GmbH Rostock.
- Completed
- Registry status
- 75
- Enrollment target
NCT03866590: Completed study, sponsored by CENTOGENE GmbH Rostock.
NCT03866590 is a clinical trial that has completed, run by CENTOGENE GmbH Rostock. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03866590 has completed, sponsored by CENTOGENE GmbH Rostock.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
Pyruvate kinase deficiency (PKD) is the most common red cell glycolytic enzyme defect causing hereditary non-spherocytic hemolytic anemia, caused by mutations in the PKLR gene. The main goal of this study is the diagnosis of pyruvate kinase deficiency in patients who exhibit chronic anaemia and/or splenomegaly and/or judiance and/or hyperbilirubinemia and/or history of prolonged neonatal jaundice and/ or cholelithiasis of undetermined aetiology.
Primary Outcome
Number of identified pyruvate kinase deficiency patients, which showing a mutation/pathogenic variant in their PKLR gene, within a cohort of 16.000 suspected cases via using respective patients' dry blood sample for confirmatory testing (next generation sequencing of PKLR gene)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2021-05-31 |
What the finished NCT03866590 record still lists
NCT03866590 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03866590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03866590 about?
NCT03866590 is a clinical study titled "Pyruvate Kinase Deficiency Epidemiological Study (PIECE)". Pyruvate kinase deficiency (PKD) is the most common red cell glycolytic enzyme defect causing hereditary non-spherocytic hemolytic anemia, caused by mutations in the PKLR gene. The main goal of this study is the diagnosis of pyruvate kinase deficiency in patients who exhibit chronic anaemia and/or s...
What is the current status of trial NCT03866590?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2020-01-13. Estimated completion is 2021-05-31.
Who is sponsoring clinical trial NCT03866590?
This trial is sponsored by CENTOGENE GmbH Rostock, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI